35 бъдат променени и по тази причина, основавайки се на фармакокинетиката, не е необходимо коригиране на дозата.
Consequently, unbound concentrations of fondaparinux are expected to be unchanged in patients with mild to moderate hepatic impairment, and therefore, no dose adjustment is necessary based on pharmacokinetics.